

# Joseph L Izzo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4105376/joseph-l-izzo-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

15,125  
citations

14  
h-index

45  
g-index

45  
ext. papers

16,668  
ext. citations

6  
avg, IF

5.54  
L-index

#	Paper	IF	Citations
43	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 2560-72	27.4	13587
42	Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. <i>Hypertension</i> , <b>2000</b> , 35, 1021-4	8.5	311
41	Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. <i>Circulation</i> , <b>2003</b> , 108, 1592-8	16.7	240
40	Pet Ownership, but Not ACE Inhibitor Therapy, Blunts Home Blood Pressure Responses to Mental Stress. <i>Hypertension</i> , <b>2001</b> , 38, 815-820	8.5	212
39	Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. <i>Circulation</i> , <b>2002</b> , 105, 2955-61	16.7	190
38	Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1077-1084	27.4	124
37	Arterial stiffness and the systolic hypertension syndrome. <i>Current Opinion in Cardiology</i> , <b>2004</b> , 19, 341-52.1	52.1	114
36	Arterial Stiffness: Going a Step Beyond. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 1223-1233	2.3	47
35	Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2098-2109	16.7	39
34	Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 36-44	2.3	37
33	Brachial vs. central systolic pressure and pulse wave transmission indicators: a critical analysis. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 1433-42	2.3	31
32	Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 485-93	2.3	28
31	Pulse Wave Velocities Derived From Cuff Ambulatory Pulse Wave Analysis. <i>Hypertension</i> , <b>2019</b> , 74, 111-118.6	18.6	25
30	Hypertension in diverse populations: a New York State Medicaid clinical guidance document. <i>Journal of the American Society of Hypertension</i> , <b>2011</b> , 5, 208-29		15
29	Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 45-8	2.3	13
28	Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. <i>Journal of the American Society of Hypertension</i> , <b>2012</b> , 6, 117-23		12
27	Prehypertension: demographics, pathophysiology, and treatment. <i>Current Hypertension Reports</i> , <b>2007</b> , 9, 264-8	4.7	12

26	Heparin attenuates norepinephrine-induced vasoconstriction. <i>Vascular Medicine</i> , <b>1998</b> , 3, 95-100	3.3	11
25	Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 526-35		10
24	Pulse contour analysis and augmentation index: it's time to move beyond cuff blood pressure measurement. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, 1S-2S	2.3	10
23	Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 143-150	2.3	7
22	Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. <i>Journal of the American Society of Hypertension</i> , <b>2012</b> , 6, 399-404		6
21	Value of Angiotensin receptor blocker therapy in diabetes. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 290-5	2.3	6
20	Diameter, pressure and compliance relationships in dorsal hand veins. <i>Vascular Medicine</i> , <b>2001</b> , 6, 97-102	3.3	6
19	Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists. <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 11-9, 31	2.3	5
18	Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1183-1190	2.3	4
17	Are there benefits of antihypertensive therapy beyond blood pressure lowering?. <i>Current Hypertension Reports</i> , <b>2010</b> , 12, 440-7	4.7	4
16	Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment. <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 3-10	2.3	4
15	Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 922-928	2.3	3
14	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007891	7.6	3
13	Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2011</b> , 5, 169-78	3.4	2
12	Your drug, my drug, or our drugs: how aggressive should we be with antihypertensive therapy?. <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 5-7	2.3	2
11	Controversies in hypertension: is lower blood pressure always better?. <i>Journal of the American Society of Hypertension</i> , <b>2016</b> , 10, 618-20		2
10	Should age determine hypertension management? Recommendations from current guidelines. <i>Journal of the American Society of Hypertension</i> , <b>2016</b> , 10, 7-9		1
9	Response to "Central blood pressure physiology" a (more) critical review (Schultz et al.). <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 692	2.3	1

- 8 Improved medical records improve hypertension management: a wake up call to payers and providers. *Journal of Clinical Hypertension*, **2002**, 4, 413-4 2.3 1
- 7 Age should not be a primary consideration in the management of hypertension. *Journal of the American Society of Hypertension*, **2016**, 10, 12-5
- 6 Response to "A Short Insight on Two Different Aspects of Arterial Stiffness"; Moving Forward or Backward?. *American Journal of Hypertension*, **2017**, 30, e3-e4 2.3
- 5 Is postural adaptation impaired by hardened arteries?. *The American Journal of Geriatric Cardiology*, **2005**, 14, 262-4
- 4 Renal denervation for human hypertension: is there a future?. *Journal of the American Society of Hypertension*, **2016**, 10, 390-2
- 3 Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities. *Journal of Clinical Hypertension*, **2019**, 21, 204-207 2.3
- 2 Calcium channel blockers in hypertension. Is there still a controversy?. *Aging Clinical and Experimental Research*, **2005**, 17, 1-5 4.8
- 1 Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg **2011**, 121, 303-9